We used immunohistochemical staining to assess protein over-expression of glial cell-derived neurotrophic factor (GDNF) and its RET receptor tyrosine kinase in patients with pancreatic cancer and benign pancreatic neoplasm, and assessed correlations with clinicopathological features and prognosis. Surgically resected pancreatic cancer patients (40/58, 68.9%) showed positive GDNF immunostaining, a significantly higher frequency than in patients with benign pancreatic tumour (3/11, 27.3%). Intrapancreatic neural invasion by cancer cells was significantly related to over-expression of GDNF. Strongly positive expression of GDNF was significantly more frequent than lesser grades of expression in patients with severe back pain before and 12 months after surgery. Expression of RET was significantly related to lymphatic invasion, survival rate after tumour resection and degree of tumour cell differentiation. We conclude that GDNF may be important in pancreatic cancer proliferation and metastasis, especially in patients with perineural invasion. Strongly positive expression of GDNF may be an indication for early intensified radiotherapy.
Introduction
Pancreatic carcinoma cells exhibit a pronounced tendency to invade along and through intra-and extrapancreatic nerves, even during the early stage of the disease. This spreading of tumour cells by perineural invasion is one of the clinicopathological features of pancreatic carcinoma and is an important prognostic factor. 1 -3 Glial cell-derived neurotrophic factor (GDNF) was identified in 1993 as a protein secreted by rat glial B49 cells that promotes Q Zeng, Y Cheng, Q Zhu et al.
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the survival and differentiation of dopaminergic neurons. 4 GDNF is also involved in the development of the enteric nervous system, in the morphogenesis of the kidneys and in the regulation of spermatogenesis, 5,6 and can promote invasion of tissues by pancreatic cancer cells. 7 The RET receptor tyrosine kinase was first described as an oncogene activated by DNA rearrangement during transfection. 6, 7 RET is involved in the development of several cancers, such as human pancreatic carcinoma and thyroid papillary carcinoma, 8 -14 however the relationship between the clinicopathological characteristics of patients with pancreatic cancer and the overexpression of GDNF and RET is not clear. In order to observe the relationship between the expression levels of GDNF and RET, and the clinicopathology and prognosis of pancreatic cancer, we performed immunohistochemical staining of GDNF and RET in tissues from patients with pancreatic cancer.
Patients and methods

PATIENTS AND SPECIMENS
The specimens of pancreatic cancer tissue used in this study were obtained from samples resected from male and female patients undergoing radical pancreatoduodenectomy for adenocarcinoma of the pancreas at the Department of General Surgery, the First Affiliated Hospital of Wenzhou Medical College between June 1999 and November 2005. None of the patients in the study received either chemotherapy or radiotherapy. We also investigated pancreatic tissue specimens from patients with benign pancreatic neoplasm (including mucous cystoadenoma, serous cystoadenoma and cyst-solid papillary tumour) and used normal background pancreatic tissue from around the pancreatic neoplasms as a control for immunohistochemistry.
Histological studies were conducted according to the Rules for the Study of Pancreatic Cancer of the International Union Against Cancer (UICC). Ethical approval was provided by the Ethics Committee of the First Affiliated Hospital of Wenzhou Medical College (No. 20050201-2) and informed consent was obtained from eligible participants.
IMMUNOHISTOCHEMISTRY
A two-step immunohistochemical staining method (EnVision™; Dako, Hamburg, Germany) was performed, with modification to the manufacturer's protocol. 15 The specimens were fixed with formalin, routinely embedded in paraffin, and cut into 4 µm sections. Each section was stained with haematoxylin-eosin to confirm a diagnosis of pancreatic neoplasm. After deparaffination and dehydration, the tissue sections were placed in a 600 W microwave oven in 0.01 mol/l sodium citrate buffer (pH 6.0) for 8 min and then exposed to 3% H 2 O 2 for 10 min to block endogenous peroxidase. All sections were then immersed in non-immune serum (blocking reagent) for 5 min to block non-specific immunoglobulin-binding sites. After removal of excess serum, primary antibodies for GDNF and its RET receptor, diluted 1:50, were added to the sections, which were then incubated overnight at 4°C. After washing with phosphate-buffered saline (PBS; 0.01 M, pH 7.4), sections were incubated with broadspectrum poly-horseradish peroxidase conjugate as secondary antibody for 60 min at room temperature. After again washing with PBS, sections were stained for 8 min with 0.05% 3,3′-diaminobenzidine tetrahydrochloride, freshly prepared in Tris/hydroxymethylaminomethane buffer Q Zeng, Y Cheng, Q Zhu et al. Over-expression of GDNF and RET in pancreatic cancer containing 0.03% H 2 O 2 for 5 -10 min, counterstained with haematoxylin, dehydrated and mounted. As a negative control, staining was also performed without the primary antibodies for GDNF and its RET receptor.
Anti-GDNF (h-134) rabbit polyclonal immunoglobulin G was purchased from Biovision Biotechnology (Palo Alto, CA, USA), and monoclonal mouse anti-human RET oncoprotein from Beijing Zhongshan Golden Bridge Biotechnology (Beijing, China).
EVALUATION OF IMMUNOHISTOCHEMICAL STAINING
Immunohistochemical staining of the pancreatic tissues was graded as follows: 16 grade 0, < 10% of cells stained; grade 1, 10 -29% of cells stained; grade 2, 30 -49% cells stained; grade 3, > 50% cells stained. Grades 1 -3 were considered positive, with grade 3 being considered strongly positive. All slides were evaluated by a single pathologist who was blind to all clinical data.
ASSESSMENT OF ABDOMINAL AND BACK PAIN
Pain was assessed in all patients before surgery and 12 months after surgery, using a standardized questionnaire. 17 The degree of pain was defined as follows: 0, no pain; 1, mild pain (abdominal discomfort or pain not requiring analgesics or not disabling); 2, moderate pain (pain controlled by nonnarcotic analgesics); 3, severe pain (pain that required narcotic analgesics and was disabling).
STATISTICAL ANALYSIS
Statistical analysis was performed with SPSS ® version 12.0 (SPSS Inc., Chicago, IL, USA). Survival analyses were performed using the Kaplan-Meier method, and differences in survival among subjects were compared using the log-rank test. Other parameters were compared using Student's t test and the χ 2 test. P < 0.05 was regarded as indicating statistical significance.
Results
Pancreatic cancer tissue was obtained from 58 patients (40 men and 18 women), of mean age 56.4 years (range 29 -83 years). The 11 patients with benign pancreatic neoplasm from whom control tissue was taken included five patients with mucous cystoadenoma, four with serous cystoadenoma and two with cyst-solid papillary tumour.
EXPRESSION AND LOCALIZATION OF GDNF AND RET IN NORMAL, BENIGN AND MALIGNANT TISSUES
Immunohistochemical staining revealed that, in normal tissue, GDNF was expressed slightly in the ductal cells but not in the acinar cells; stronger staining was detected in endocrine cells and intrapancreatic nerves. Tissue specimens from 68.9% (40/58) of patients with pancreatic adenocarcinoma were positive for GDNF (grade > 1, > 10% cells stained) ( Fig. 1) ; 28 of the 40 specimens were strongly positive (grade 3, > 50% cells stained). The percentage of positive specimens was significantly higher for pancreatic adenocarcinoma tissue than for benign pancreatic tumour tissue (3/11, 27.3%) (χ 2 = 6.845, P = 0.015).
Expression of RET was apparent in the exocrine cells, especially acinar cells, but not in endocrine cells or nerve structures. The rates of expression of RET in pancreatic adenocarcinoma (Fig. 2) and benign pancreatic tumour tissue were 50.0% (29/58) and 27.3% (3/11) respectively; the difference was not significant. Table 1 shows that the frequency of positivity for GDNF in pancreatic cancer patients with perineural invasion (16/18, 88.9%) was significantly greater than in patients without perineural invasion (24/40, 60.0%) (χ 2 = 5.278, P = 0.03). This indicates that GDNF was expressed in pancreatic tissue associated with neural invasion (Fig. 3) but not with lymphatic or venous invasion.
RELATIONSHIPS BETWEEN EXPRESSION OF GDNF, RET AND CLINICOPATHOLOGICAL FEATURES
The incidence of strongly positive expression (grade 3) of GDNF was significantly greater than the incidence of expression grades 0 -2 in patients with a higher degree of back pain before surgery (P = 0.045) and 12 months after surgery (P = 0.028) ( Table 2) .
The frequency of expression of RET in pancreatic cancer patients with lymph node metastasis (14/16, 87.5%) was significantly greater than in patients without lymph node metastasis (15/42, 35.7%,) (χ 2 = 12.429, P = 0.001) ( Table 1 ). The frequency of RET expression in patients with welldifferentiated pancreatic carcinoma (12/14, 85.7%) was significantly higher than that in patients with moderately or poorly differentiated pancreatic carcinoma (17/44, 38.6%) (χ 2 = 9.416, P = 0.005) (Table 1) .
SURVIVAL RATE IN RELATION TO EXPRESSION OF RET
The median survival time of patients with pancreatic cancer who were positive for RET staining was 9 months compared with 28 months for patients who were negative for RET staining (log-rank statistic = 5.91, P = 0.015) ( Fig. 4 ).
Discussion
Pancreatic cancer characteristically demonstrates a high potential for neural invasion, although the mechanisms are not yet fully elucidated. 1,2 The neural tissue surrounding the pancreas is composed mainly of autonomic nerves radiating from the coeliac ganglion. The ganglion itself consists of neurons and other supporting
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Without (n = 40) 16 a GDNF and RET expression, based on immunohistochemical staining of pancreatic tissues: negative is grade 0, < 10% of cells stained; positive is grade > 1, > 10% cells stained. GDNF, glial cell-derived neurotrophic factor; NS, not statistically significant (P > 0.05).
TABLE 1: Relationship between expression of GDNF and RET, and clinicopathological features of pancreatic cancer (data show numbers and percentages of patients)
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2: Relationship between expression of glial cell-derived neurotrophic factor (GDNF) and back pain in patients with pancreatic cancer, scored before surgery and 12 months after surgery (data show numbers of patients)
FIGURE 3: Expression of GDNF protein in pancreatic cancer tissue associated with neural invasion, assessed by a modified two-step immunohistochemical staining method (EnVision™) elements, such as Schwann, glial and mesenchymal cells, all of which are capable of producing a variety of neurotrophic factors, such as nerve growth factor, brain-derived neurotrophic factor, GDNF and neurturin. 3 -7 The GDNF family consists of four closely related members: GDNF, neurturin, perdephin and artemin, 16, 18, 19 all Q Zeng, Y Cheng, Q Zhu et al.
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of which signal through a unique multicomponent receptor complex.
Neurotrophic factors can activate pancreatic cancers and facilitate their extension along nerves. 7,16,18 -21 Ito et al. 16 reported that invasion by pancreatic cancer cells could be induced by GDNF in vitro and that the coeliac neural plexus produces GDNF. Moreover, they reported that intrapancreatic neural invasion was significantly related to the expression of GDNF (P = 0.047). Also, Iwahashi et al. 22 have reported that neural invasion is significantly related to the expression of GDNF in bile duct cancers.
Our results revealed that GDNF was expressed slightly in ductal cells but not in acinar cells; stronger staining was detected in endocrine cells and intrapancreatic nerves. Moreover, 40 of 58 patients with pancreatic adenocarcinoma were positive for GDNF (with strong staining in 28 of them), a frequency that was significantly higher than in patients with benign pancreatic tumour. The different rates of expression of GDNF in normal tissue and in benign and malignant pancreatic tumour suggest that GDNF may play a role in the malignant transformation of pancreatic epithelia.
The over-expression of GDNF protein in pancreatic cancer patients with perineural invasion (16/18, 88 .9%) was significantly higher that in patients without perineural invasion (24/40, 60.0%). Furthermore, we 
found that strongly positive GDNF expression was associated with a higher degree of abdominal and back pain before and 12 months after surgery. Abdominal and back pain in pancreatic cancer patients arises because neighbouring tissues and nerves are invaded by cancer cells, and it benefits from limited-field radiotherapy. Giving early intensified limited-field radiotherapy may benefit patients with pancreatic cancer who express GDNF strongly.
The RET receptor tyrosine kinase was first described as an oncogene activated by DNA rearrangement during transfection. 5,9 The human ret gene contains 21 exons, and alternative splicing at the 5′ and 3′ ends of the RET heterogenous nuclear RNA has been reported. 21 Mutations of the ret protooncogene are responsible for several inherited human diseases and may function as genetic modifiers of disease. Alterations in the gene encoding RET, which forms complexes with the receptors of all the forms of GDNF, are responsible for multiple endocrine neoplasia types 2A and 2B and familial medullary thyroid carcinoma. 10 A study by Sawai et al. 19 suggested that GDNF increased pancreatic cancer cell proliferation and invasion, the process being mediated by RET; the effect of GDNF was significantly greater in cells with the G691S ret polymorphism (P < 0.01) and this polymorphism correlated with increased activation of the downstream extracellular signal-regulated kinase pathway, and overexpression of G691S ret increased pancreatic cancer cell invasion. Moreover, the G691S ret polymorphism was also detected in human pancreatic tumours and represented a somatic mutation in some patients.
In the present study, the expression rates of RET in pancreatic adenocarcinoma and benign pancreatic tumours were 50.0% (29/58) and 27.3% (3/11), respectively; the difference was not significant. In addition, the rate of RET expression in patients with well-differentiated pancreatic carcinoma was significantly higher than in patients with moderately or poorly pancreatic differentiated carcinoma. The reason for these results is not currently known. Our study also showed that the prognosis of pancreatic cancer patients with overexpression of RET was poor, with a higher incidence of lymph node metastasis and a shorter median survival time, in accordance with the results of Ito et al. 16 The molecular mechanism of GDNFpromoted perineural invasion by pancreatic cancer cells has been investigated in several studies. For example, in vitro cell migration assay revealed that the migration of cells expressing GDNF was enhanced by cocultivation with cells expressing RET and GDNF family co-receptor α1 (GFRα1). 7 Cell migration has also shown to be increased by conditioned medium from GDNF-treated cells that expressed RET and GFRα1, and the increase in integrin expression induced by GDNF signalling through the GDNF receptor strongly influenced invasion and adhesion to the extracellular membrane by pancreatic cancer cells. 23 We conclude that GDNF may play an important role in the proliferation and metastasis of pancreatic cancer, especially in patients with perineural invasion. Furthermore, strongly positive expression of GDNF may be an indication for early intensified radiotherapy. The expression of RET in cancer cells may be a useful clinical prognostic marker for pancreatic cancer.
